share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K：外国发行人报告（业绩相关）
SEC announcement ·  03/21 13:56
Moomoo AI 已提取核心信息
Cybin Inc. (Cybin), a biopharmaceutical company, has announced the completion of a private placement offering of common shares, raising gross proceeds of up to $150 million. The offering was conducted on a 'commercially reasonable efforts' basis by Bloom Burton Securities Inc. (Lead Agent) and Haywood Securities Inc. (collectively, the 'Agents'). The shares were priced at $0.43 each, with the event dated March 19, 2024. The offering was made to purchasers in Canada, the United States, and offshore jurisdictions, exempt from registration requirements under U.S. securities laws. The Agents were entitled to an offering fee of 6.0% of the aggregate gross proceeds, reduced to 3.0% for president's list purchasers introduced by Cybin. The offering aimed to issue and sell common shares without underwriter liability, with the Agents appointing other dealers to assist in the offering. The Agents were responsible for their remuneration, payable from their offering fee. The offering's completion was subject to customary closing conditions, including regulatory approvals and the execution of subscription agreements with purchasers.
Cybin Inc. (Cybin), a biopharmaceutical company, has announced the completion of a private placement offering of common shares, raising gross proceeds of up to $150 million. The offering was conducted on a 'commercially reasonable efforts' basis by Bloom Burton Securities Inc. (Lead Agent) and Haywood Securities Inc. (collectively, the 'Agents'). The shares were priced at $0.43 each, with the event dated March 19, 2024. The offering was made to purchasers in Canada, the United States, and offshore jurisdictions, exempt from registration requirements under U.S. securities laws. The Agents were entitled to an offering fee of 6.0% of the aggregate gross proceeds, reduced to 3.0% for president's list purchasers introduced by Cybin. The offering aimed to issue and sell common shares without underwriter liability, with the Agents appointing other dealers to assist in the offering. The Agents were responsible for their remuneration, payable from their offering fee. The offering's completion was subject to customary closing conditions, including regulatory approvals and the execution of subscription agreements with purchasers.
生物制药公司Cybin Inc.（Cybin）宣布完成普通股的私募发行，总收益高达1.5亿美元。此次发行是由布鲁姆·伯顿证券公司（牵头代理人）和海伍德证券公司（统称为 “代理人”）在 “商业上合理的努力” 的基础上进行的。这些股票的定价为每股0.43美元，活动日期为2024年3月19日。此次发行是针对加拿大、美国和离岸司法管辖区的购买者进行的，不受美国证券法规定的注册要求的约束。代理商有权获得总收益的6.0％的发行费，对于Cybin推出的总裁名单购买者，则降至3.0％。此次发行旨在发行和出售普通股，无需承销商承担责任，代理商将指定其他交易商协助发行。代理商负责支付报酬，从报价中支付。此次发行的完成取决于惯例成交条件，包括监管部门的批准和与买方签订的订阅协议的执行。
生物制药公司Cybin Inc.（Cybin）宣布完成普通股的私募发行，总收益高达1.5亿美元。此次发行是由布鲁姆·伯顿证券公司（牵头代理人）和海伍德证券公司（统称为 “代理人”）在 “商业上合理的努力” 的基础上进行的。这些股票的定价为每股0.43美元，活动日期为2024年3月19日。此次发行是针对加拿大、美国和离岸司法管辖区的购买者进行的，不受美国证券法规定的注册要求的约束。代理商有权获得总收益的6.0％的发行费，对于Cybin推出的总裁名单购买者，则降至3.0％。此次发行旨在发行和出售普通股，无需承销商承担责任，代理商将指定其他交易商协助发行。代理商负责支付报酬，从报价中支付。此次发行的完成取决于惯例成交条件，包括监管部门的批准和与买方签订的订阅协议的执行。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息